These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 34206051)

  • 1. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
    Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.
    Salewski I; Kuntoff S; Kuemmel A; Feldtmann R; Felix SB; Henze L; Junghanss C; Maletzki C
    Cancer Immunol Immunother; 2021 Dec; 70(12):3405-3419. PubMed ID: 33870463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
    Maletzki C; Wiegele L; Nassar I; Stenzel J; Junghanss C
    J Immunother Cancer; 2019 Jan; 7(1):8. PubMed ID: 30630527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
    Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
    Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
    Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
    Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of mismatch repair deficiency in sarcomas.
    Doyle LA; Nowak JA; Nathenson MJ; Thornton K; Wagner AJ; Johnson JM; Albrayak A; George S; Sholl LM
    Mod Pathol; 2019 Jul; 32(7):977-987. PubMed ID: 30765880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
    Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
    Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
    Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
    Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).
    Leenders EKSM; Westdorp H; Brüggemann RJ; Loeffen J; Kratz C; Burn J; Hoogerbrugge N; Jongmans MCJ
    Eur J Hum Genet; 2018 Oct; 26(10):1417-1423. PubMed ID: 29904176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
    Asaka S; Yen TT; Wang TL; Shih IM; Gaillard S
    Mod Pathol; 2019 Apr; 32(4):576-584. PubMed ID: 30401949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
    Solomon A; Alteber Z; Bassan D; Sharbi-Yunger A; Esbit S; Tzehoval E; Eisenbach L
    Int J Cancer; 2022 Jul; 151(1):107-119. PubMed ID: 35179790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
    Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy.
    Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI
    Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.